TrialTrials2024

The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.

Lisa-Marie Brunner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.